Ocular hyperemia with netarsudil/latanoprost fixed combination in glaucoma: an exploratory association analysis of tolerability outcomes by prior topical therapy and baseline ocular hyperemia.
Holló Gábor G
This post hoc analysis of MERCURY-3 evaluates factors associated with baseline ocular hyperemia and tolerability outcomes with netarsudil/latanoprost fixed combination (NET/LAT). MERCURY-3 was a prospective, randomized, double-masked, multicenter, Phase 3, European trial. Adults with open-angle glaucoma or ocular hypertension inadequately controlled on topical therapy were randomized to once-daily NET/LAT (n = 218) or bimatoprost/timolol fixed combination (BIM/TIM; n = 212) for 6 months. Patients were stratified by baseline ocular hyperemia status (none vs any grade) and associations with prior treatment, adverse events (AEs), and hyperemia evolution evaluated. In the NET/LAT arm, prior combination therapy was associated with a greater prevalence of baseline ocular hyperemia than prior monotherapy (distribution: p = 0.003). Patients with baseline hyperemia experienced higher rates of AEs (85% vs 63%), ocular treatment-related AEs (74% vs 39%), and conjunctival hyperemia (45% vs 26%) during treatment. Ocular hyperemia remained predominantly mild throughout follow-up, with a more stable severity trajectory linked to prior monotherapy compared with prior combination therapy. No comparable associations were observed with BIM/TIM. Prior treatment complexity and baseline ocular hyperemia status are associated with tolerability outcomes during NET/LAT therapy. These exploratory findings suggest that earlier step-up after monotherapy could be associated with more favorable tolerability. CT.gov identifier: NCT03284853.